Triprolidine

RESPIRATORY SYSTEM

Key facts

Triprolidine is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 1983. DrugCentral lists 2 molecular targets, including HRH1 and HRH1. Recorded indications include Allergic conjunctivitis, Allergic rhinitis, Common cold and Dermatographic urticaria.

• Approval status: ofp (first approved 1983 by the FDA).
• Molecular targets: HRH1 and HRH1 (2 listed in DrugCentral).
• Indications: Allergic conjunctivitis, Allergic rhinitis, Common cold, Dermatographic urticaria and Itching of skin and others.
• ATC code: R06AX07 (Other antihistamines for systemic use).
• Molecular formula: C19H22N2; molecular weight 278.40 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (9)

• Allergic conjunctivitis
• Allergic rhinitis
• Common cold
• Dermatographic urticaria
• Itching of skin
• Nasal discharge
• Seasonal allergic rhinitis
• Urticaria
• Vasomotor rhinitis

Contraindications (52)

• Acidosis
• Acute abdominal pain
• Acute exacerbation of asthma
• Acute hepatitis
• Acute pancreatitis
• Angle-closure glaucoma
• Arterial thrombosis
• Arteriosclerotic vascular disease
• Asthenia
• Benign intracranial hypertension
• Benign prostatic hyperplasia
• Bladder outflow obstruction
• Bradycardia
• Central nervous system depression
• Chronic disease of respiratory system
• Chronic heart failure
• Chronic idiopathic constipation
• Conduction disorder of the heart
• Coronary arteriosclerosis
• Decreased respiratory function
• Dependent drug abuse
• Diabetes mellitus
• Disease of liver
• Disorder of coronary artery
• Disorder of gallbladder
• Drug AND/OR toxin-induced diarrhea
• Dysfunction of sphincter of Oddi
• Epilepsy
• Hypertensive disorder
• Hypertensive urgency
• + 22 more

Mechanism & targets

Molecular targets (2)

Target	Gene	Action	Activity
Histamine H1 receptor	HRH1	antagonist	Ki 9.90
Histamine H1 receptor	HRH1	unknown	Kd 9.90

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1983-05-17	FDA	—	SANDOZ

ATC classification

ATC code	Therapeutic hierarchy
R06AX07	RESPIRATORY SYSTEM › ANTIHISTAMINES FOR SYSTEMIC USE › ANTIHISTAMINES FOR SYSTEMIC USE › Other antihistamines for systemic use

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Ulcer haemorrhage	314.8
Pulmonary fibrosis	189.8
Type 2 diabetes mellitus	185.3
Psoriatic arthropathy	173.6
Injury	170.4
Oedema	168.9
Liver injury	160.9
Pericarditis	151.8
Mobility decreased	143.4
Sleep disorder	138.0
Migraine	132.8
Pemphigus	131.0

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Triprolidine is on its molecule page.

• Molecular formula: C₁₉H₂₂N₂
• Molecular weight: 278.40 g/mol
• CAS number: —
• InChIKey: CBEQULMOCCWAQT-WOJGMQOQSA-N
• PubChem CID: 5282443

CC1=CC=C(C=C1)C(=C/CN1CCCC1)\C1=CC=CC=N1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Triprolidine used for?

DrugCentral lists the following indications for Triprolidine: Allergic conjunctivitis, Allergic rhinitis, Common cold, Dermatographic urticaria, Itching of skin, Nasal discharge, Seasonal allergic rhinitis and Urticaria and others.

How does Triprolidine work?

Its molecular targets in DrugCentral include HRH1 (antagonist) and HRH1.

When was Triprolidine first approved?

Triprolidine was first approved by the FDA in 1983.

What is the chemical formula of Triprolidine?

Triprolidine has the molecular formula C19H22N2 and a molecular weight of 278.40 g/mol.

Sources

• DrugCentral drug card 2763 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3188034 — compound record and bioactivity
• PubChem CID 5282443 — chemical identifiers
• DrugBank DB00427 — drug record
• FDA UNII 2L8T9S52QM — substance identity
• DailyMed: FDA labels for Triprolidine — current prescribing information (label search)
• UniProt P35367 (HRH1) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.